secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-037161
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports FY2023 net loss $125M, cash $322M; clinical updates for naporafenib and ERAS-801
--------------------------------------------------------------------------------

- Net loss $125M ($0.83/share) for FY2023 vs $242.8M ($1.99/share) in prior year; R&D expenses $103.8M.
- Cash, equivalents, marketable securities $322M as of Dec 31, 2023, down from $435.6M.
- Gained FDA Fast Track Designation for naporafenib + trametinib in NRASm melanoma; planned Phase 3 SEACRAFT-2 initiation H1 2024.
- Entered clinical trial collaboration with Novartis for trametinib supply for naporafenib trials at no cost.
- Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), ERAS-801 (THUNDERBBOLT-1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/0000950170-24-037161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/eras-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer